Calliditas Therapeutics AB American Depositary Shares
CALT
CALT was delisted on the 20th of September, 2024.
17 hedge funds and large institutions have $16.7M invested in Calliditas Therapeutics AB American Depositary Shares in 2022 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 4 increasing their positions, 6 reducing their positions, and 2 closing their positions.
1,035% more call options, than puts
Call options by funds: $193K | Put options by funds: $17K
0% more funds holding
Funds holding: 17 → 17 (0)
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
33% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 6
38% less capital invested
Capital invested by funds: $26.8M → $16.7M (-$10.1M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
+$231K |
| 2 |
CG
Cutler Group
San Francisco,
California
|
+$32.7K |
| 3 |
IIM
Ironwood Investment Management
Boston,
Massachusetts
|
+$30K |
| 4 |
Wells Fargo
San Francisco,
California
|
+$6.92K |
| 5 |
CAPTRUST Financial Advisors
Raleigh,
North Carolina
|
+$1.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tang Capital Management
San Diego,
California
|
-$2.48M |
| 2 |
Marshall Wace
London,
United Kingdom
|
-$1.06M |
| 3 |
Optiver Holding
Amsterdam,
Netherlands
|
-$839K |
| 4 |
Morgan Stanley
New York
|
-$40.6K |
| 5 |
Simplex Trading
Chicago,
Illinois
|
-$29K |
CALT Hedge Fund Activity: Q1 2022 in Review
17 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Calliditas Therapeutics AB American Depositary Shares (CALT) for Q1 2022, worth a combined $16.7M — down 38% from $26.8M a quarter earlier.
Fund positioning in CALT was balanced in Q1 2022: 2 funds opened new positions, 2 closed out, 4 added to existing stakes and 6 trimmed.
The largest buyer was Jane Street, opening a new position worth an estimated $231K. The largest seller was Tang Capital Management, exiting entirely with an estimated $2.48M sold.
- 17 institutional investors held Calliditas Therapeutics AB American Depositary Shares (CALT) as of Q1 2022, unchanged from Q4 2021.
- Funds reported $16.7M of Calliditas Therapeutics AB American Depositary Shares stock for Q1 2022, down 38% quarter-over-quarter.
- 2 funds opened new Calliditas Therapeutics AB American Depositary Shares positions in Q1 2022 and 2 closed out, a net change of 0 holders.
- The largest Calliditas Therapeutics AB American Depositary Shares buyer in Q1 2022 was Jane Street, an estimated $231K added.
- The largest Calliditas Therapeutics AB American Depositary Shares seller in Q1 2022 was Tang Capital Management, an estimated $2.48M sold.
Based on aggregated 13F filings for Q1 2022.